Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

September 28, 2022

https://www.globenewswire.com/news-release/2022/09/28/2524731/0/en/Cellectis-Appoints-Mark-Frattini-M-D-Ph-D-as-Chief-Medical-Officer.html

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Mark Frattini, M.D., Ph.D., as Chief Medical Officer, effective immediately.

Read more at globenewswire.com

Related news for (CLLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.